Evotec's Two-Front Strategy: New Alliances Emerge as Guidance Cuts Reshape the Investment Case
Published on 08/07/2026 at 18:11 | Redaktion boerse-global.de
The Hamburg-based drug developer Evotec is presenting investors with a study in contrasts this week. On Thursday, the company unveiled a pair of fresh collaborations—an artificial intelligence-driven research pact with Odyssey Therapeutics targeting autoimmune and inflammatory conditions, alongside a $2.5 million grant from the Gates Foundation earmarked for next-generation tuberculosis therapies. The announcements arrive barely a month after a profit warning that sliced billions in market value and forced a dramatic rewrite of the company's 2026 financial targets.
Shares traded at €3.49 on Friday, up 0.81 percent, yet the stock remains just 9.34 percent above its 52-week low of €3.19. The modest bounce does little to erase the damage: over the past month, the equity has shed 28.28 percent, and year-to-date losses stand at 35.96 percent.
The Numbers Behind the Reset
The root of the sell-off lies in guidance issued on July 13, when Evotec slashed its full-year revenue forecast from €700–780 million to €570–610 million. The adjusted EBITDA outlook turned even more starkly negative, now projecting a loss of €70–105 million against the previous expectation of breakeven to €40 million in profit. Preliminary first-half figures showed revenue of €300.1 million and an adjusted EBITDA deficit of €42.7 million.
Management attributes roughly 40 percent of the shortfall to delayed milestone payments from existing partnerships—funds the company insists are merely deferred into 2027 rather than lost. Another 45 percent stems from extended negotiation timelines for new collaborations, which are unlikely to contribute meaningful revenue this year. The remaining 15 percent reflects a slower conversion of sales activity into recognized revenue, though Evotec simultaneously points to improving commercial momentum.
Should investors sell immediately? Or is it worth buying Evotec?
That mixed picture extends to the segment level. Net sales in Discovery & Preclinical Development excluding strategic partners climbed approximately 28 percent in the first half—evidence that the underlying business retains vitality even as anchor partnerships sputter.
Restructuring Intensifies
The company's "Horizon" transformation program is gathering pace alongside the operational challenges. Evotec plans to consolidate from 19 sites to just ten, having already set aside €75 million in the first quarter for personnel measures and impairments. Targeted structural savings of roughly €75 million are expected by the end of 2027, with 20 to 30 percent of that total slated to take effect during 2026.
The new Odyssey collaboration suggests the cost discipline hasn't stifled innovation ambitions. The partnership will embed artificial intelligence methods into early-stage drug discovery for autoimmune and inflammatory disease therapies, though Evotec has not disclosed financial terms or milestone structures. The Gates Foundation funding extends the company's long-standing work with philanthropic organizations in tuberculosis research, and Evotec has additionally joined the NURTuRE-AKI consortium investigating acute kidney failure mechanisms.
Evotec at a turning point? This analysis reveals what investors need to know now.
Divergent Analyst Reactions
The post-warning response from the sell-side has been notably split. TD Cowen trimmed its price target to €4.00 on July 15, while RBC Capital Markets maintained an "Outperform" rating with a €10.00 target the same day, citing rising order volumes in Discovery & Preclinical Development. Berenberg took the most aggressive stance, slashing its target from €9.40 to €3.60 on July 16 and downgrading the stock from "Buy" to "Hold."
Technical indicators offer limited consolation. The 14-day RSI sits at 31.6, suggesting oversold conditions, while the share price remains well below its 50-, 100-, and 200-day moving averages. The stock's trajectory over the coming weeks hinges on the full half-year report due August 13, when investors will scrutinize whether the narrative of deferred rather than lost revenue holds up—and whether the new partnerships can begin to offset a guidance framework that has fundamentally shifted the company's near-term expectations.
Ad
Evotec Stock: New Analysis - 7 August
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
